Course

Making Sense of an Increasingly Complex Treatment Paradigm in RA

0 out of 2 steps completed0%
0 Lessons

Making Sense of an Increasingly Complex Treatment Paradigm in RA

Learning Objectives

  1. Discuss the clinical importance of strong vs. conditional recommendations included within the 2015 ACR guideline for the treatment of RA
  2. List at least two overarching principles to guide RA care included within the 2015 ACR guideline
  3. Assess the state of your current practice regarding tuberculosis screening and vaccinations in patients on conventional or biologic DMARD therapy, and identify any areas for improvement
  4. Describe common barriers that influence adherence to RA treatment regimens

Accreditation Statement

The Rheumatology Nurses Society is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity offers 1.5 contact hours to participating nurses. This credit may be applied toward licensure requirements in those states that recognize American Nurses Credentialing Center’s Commission on Accreditation (ANCC-COA) accredited providers.

Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.

Sheree Carter, PhD, RN, RN-BC, is the nurse planner for this activity.

Disclosure

It is the policy of the Rheumatology Nurses Society (RNS) that the education presented within RNS-provided activities be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, RNS provides information that planners, teachers, authors, developers, and activity managers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity. Relationships that an individual may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.

Relationships are abbreviated as follows:

E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
C: Consultant
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
H: Honoraria
O: Other

Sheree Carter, PhD, RN, RN-BC, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Jacqueline Fritz, RN, MSN, CNS, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Lilly, AbbVie, Celgene, Horizon, Momenta Pharmaceuticals/A; Celgene, AbbVie, Genentech, Horizon/SB

Elizabeth Kirchner, CNP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Horizon, Novartis, UCB, Lilly, GlaxoSmithKline, Boehringer Ingelheim/AB; Crescendo Biosciences/SB.

Iris Zink, MSN, NP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Pfizer, Crescendo/A,SB; Sanofi/A; Bristol Myers-Squibb/SB.

Target Audience

The intended audience for this activity includes rheumatology nurses, rheumatology advanced practice nurses, and infusion nurses.

Content Direction

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Freelancer

Anne Jacobson, MPH, CHCP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Peer Reviewer

This newsletter was reviewed by Linda Grinnell-Merrick, MS, NP.BC. Ms. Grinnell-Merrick has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Pfizer, GlaxoSmithKline, Horizon/A; Janssen/C, SB; AbbVie, Celgene/SB.

Production Management

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Product Disclosure

This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.

ACTIVITY SUMMARY

In this issue of Rheumatology Nurse Practice, we will explore the main features of the 2015 ACR guideline for the treatment of RA, including how to interpret recommendations that carry different strengths and levels of evidence. Although clinical practice guidelines can feel overwhelming, this issue focuses on practical strategies for letting the treatment recommendations inform—rather than dictate—your approach to care of patients with RA.